Revenue grew 5.4% to $108.4B in 2026Q3 while the combined ratio tightened to 96.7%, though the thin operating margin near 3.3% and the 2025Q3 net loss of $4.0B suggest profitability remains fragile.
CVS Health Corp. (CVS) annual income statement — 30-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Revenue | 420.61B | 402.07B | 372.81B | 357.78B | 322.47B | 292.11B | 268.71B | 256.78B | 194.58B | 184.79B | 177.55B | 153.29B | 139.37B | 126.76B | 123.12B | 107.08B | 95.78B | 98.22B | 87.47B | 76.33B | 43.82B | 37.01B | 30.59B | 26.59B | 24.18B | 22.24B | 20.09B | 18.1B | 15.27B | 13.75B | 11.83B |
| Revenue Growth % | 6.73% | 7.85% | 4.2% | 10.95% | 10.39% | 8.71% | 4.65% | 31.96% | 5.3% | 4.08% | 15.82% | 9.99% | 9.94% | 2.96% | 14.98% | 11.8% | -2.48% | 12.28% | 14.6% | 74.18% | 18.41% | 20.96% | 15.07% | 9.95% | 8.72% | 10.72% | 10.99% | 18.49% | 11.08% | 16.21% | 21.18% |
| Medical Costs & Claims | 360.78B | 346.7B | 321.41B | 303.35B | 267.96B | 239.99B | 219.66B | 211.25B | 163.04B | 156.26B | 148.71B | 126.76B | 114B | 102.98B | 100.63B | 86.52B | 75.56B | 77.86B | 69.18B | 60.22B | 32.08B | 27.31B | 22.56B | 19.73B | 18.11B | 16.55B | 14.73B | 13.24B | 11.14B | 10.03B | 8.47B |
| Medical Cost Ratio % | 85.77% | 86.23% | 86.21% | 84.79% | 83.1% | 82.16% | 81.75% | 82.27% | 83.79% | 84.56% | 83.76% | 82.69% | 81.8% | 81.24% | 81.73% | 80.8% | 78.89% | 79.27% | 79.09% | 78.9% | 73.2% | 73.8% | 73.75% | 74.19% | 74.9% | 74.41% | 73.31% | 73.14% | 72.97% | 72.93% | 71.62% |
| Gross Profit | 59.84B | 55.36B | 51.4B | 54.43B | 54.5B | 52.12B | 49.05B | 45.53B | 31.54B | 28.53B | 28.83B | 26.53B | 25.37B | 23.78B | 22.49B | 20.56B | 20.22B | 20.36B | 18.29B | 16.11B | 11.74B | 9.69B | 8.03B | 6.86B | 6.07B | 5.69B | 5.36B | 4.86B | 4.13B | 3.72B | 3.36B |
| Gross Margin % | 14.23% | 13.77% | 13.79% | 15.21% | 16.9% | 17.84% | 18.25% | 17.73% | 16.21% | 15.44% | 16.24% | 17.31% | 18.2% | 18.76% | 18.27% | 19.2% | 21.11% | 20.73% | 20.91% | 21.1% | 26.8% | 26.2% | 26.25% | 25.81% | 25.1% | 25.59% | 26.69% | 26.86% | 27.03% | 27.07% | 28.38% |
| Gross Profit Growth % | - | 7.71% | -5.57% | -0.13% | 4.57% | 6.27% | 7.73% | 44.36% | 10.55% | -1.06% | 8.69% | 4.58% | 6.66% | 5.76% | 9.37% | 1.7% | -0.68% | 11.31% | 13.55% | 37.18% | 21.12% | 20.71% | 17.02% | 13.09% | 6.64% | 6.14% | 10.29% | 17.73% | 10.92% | 10.85% | 15.64% |
| Operating Expenses | 44.78B | 44.98B | 42.88B | 40.69B | 46.55B | 38.81B | 35.13B | 33.54B | 27.52B | 18.99B | 18.45B | 17.05B | 16.57B | 15.75B | 15.28B | 14.23B | 14.08B | 13.93B | 12.24B | 11.31B | 9.3B | 7.68B | 6.58B | 5.44B | 4.86B | 4.92B | 4.04B | 3.73B | 3.2B | 3.02B | 2.75B |
| OpEx / Revenue % | 10.65% | 11.19% | 11.5% | 11.37% | 14.43% | 13.29% | 13.08% | 13.06% | 14.14% | 10.28% | 10.39% | 11.12% | 11.89% | 12.42% | 12.41% | 13.29% | 14.7% | 14.19% | 14% | 14.82% | 21.22% | 20.74% | 21.5% | 20.46% | 20.11% | 22.12% | 20.11% | 20.59% | 20.94% | 21.95% | 23.27% |
| Depreciation & Amortization | 4.52B | 4.61B | 4.6B | 4.37B | 4.22B | 4.49B | 4.44B | 4.37B | 2.72B | 2.48B | 2.48B | 2.09B | 1.93B | 1.87B | 1.75B | 1.57B | 1.47B | 1.39B | 1.27B | 1.09B | 733.3M | 589.1M | 439.9M | 341.7M | 310.3M | 320.8M | 296.6M | 277.9M | 249.7M | 242.6M | 262.8M |
| Combined Ratio % | 96.42% | 97.42% | 97.72% | 96.16% | 97.53% | 95.44% | 94.82% | 95.33% | 97.93% | 94.84% | 94.15% | 93.82% | 93.69% | 93.66% | 94.14% | 94.09% | 93.59% | 93.46% | 93.09% | 93.72% | 94.43% | 94.54% | 95.25% | 94.65% | 95.01% | 96.54% | 93.42% | 93.73% | 93.91% | 94.88% | 94.89% |
| Operating Income | 15.06B | 10.38B | 8.52B | 13.74B | 7.95B | 13.31B | 13.91B | 11.99B | 4.02B | 9.54B | 10.39B | 9.47B | 8.8B | 8.04B | 7.21B | 6.33B | 6.14B | 6.42B | 6.05B | 4.79B | 2.44B | 2.02B | 1.45B | 1.42B | 1.21B | 770.6M | 1.32B | 1.14B | 930.5M | 704.1M | 604.7M |
| Operating Margin % | 3.58% | 2.58% | 2.28% | 3.84% | 2.47% | 4.56% | 5.18% | 4.67% | 2.07% | 5.16% | 5.85% | 6.18% | 6.31% | 6.34% | 5.86% | 5.91% | 6.41% | 6.54% | 6.91% | 6.28% | 5.57% | 5.46% | 4.75% | 5.35% | 4.99% | 3.46% | 6.58% | 6.27% | 6.09% | 5.12% | 5.11% |
| Operating Income Growth % | - | 21.95% | -38.03% | 72.78% | -40.24% | -4.32% | 16.05% | 198.11% | -57.84% | -8.16% | 9.61% | 7.68% | 9.48% | 11.47% | 13.88% | 3.16% | -4.48% | 6.27% | 26.13% | 96.32% | 20.9% | 38.83% | 2.18% | 18.02% | 56.53% | -41.74% | 16.49% | 22.03% | 32.15% | 16.44% | 52.62% |
| EBITDA | 19.58B | 14.99B | 13.11B | 18.11B | 12.18B | 17.8B | 18.35B | 16.36B | 6.74B | 12.02B | 12.86B | 11.57B | 10.73B | 9.91B | 8.96B | 7.9B | 7.61B | 7.81B | 7.32B | 5.89B | 3.17B | 2.61B | 1.89B | 1.77B | 1.52B | 1.09B | 1.62B | 1.41B | 1.18B | 946.7M | 867.5M |
| EBITDA Margin % | 4.66% | 3.73% | 3.52% | 5.06% | 3.78% | 6.09% | 6.83% | 6.37% | 3.46% | 6.5% | 7.24% | 7.55% | 7.7% | 7.82% | 7.28% | 7.38% | 7.94% | 7.96% | 8.37% | 7.71% | 7.25% | 7.05% | 6.19% | 6.64% | 6.27% | 4.91% | 8.06% | 7.81% | 7.73% | 6.89% | 7.33% |
| Interest Expense | 3.06B | 3.12B | 2.96B | 2.66B | 2.29B | 2.5B | 2.91B | 3.04B | 2.62B | 1.06B | 1.08B | 859M | 615M | 517M | 561M | 588M | 539M | 530M | 530M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Operating Income | -122M | 5.13B | -590M | -88M | -169M | 270M | 1.23B | -45M | -4M | 208M | 671M | 0 | 506M | -8M | 344M | -4M | -3M | -5M | -21M | 0 | 0 | 0 | 0 | 0 | 0 | -352.5M | 0 | 0 | 0 | 0 | 0 |
| Pretax Income | 12.12B | 2.14B | 6.15B | 11.17B | 5.84B | 10.54B | 9.77B | 9B | 1.41B | 8.27B | 8.64B | 8.62B | 7.68B | 7.53B | 6.3B | 5.75B | 5.6B | 5.9B | 5.54B | 4.36B | 2.23B | 1.91B | 1.4B | 1.38B | 1.16B | 709.6M | 1.24B | 1.08B | 691M | 237.6M | 643.4M |
| Pretax Margin % | 2.88% | 0.53% | 1.65% | 3.12% | 1.81% | 3.61% | 3.64% | 3.5% | 0.72% | 4.47% | 4.86% | 5.62% | 5.51% | 5.94% | 5.12% | 5.37% | 5.85% | 6.01% | 6.33% | 5.71% | 5.08% | 5.16% | 4.56% | 5.17% | 4.78% | 3.19% | 6.19% | 5.95% | 4.52% | 1.73% | 5.44% |
| Income Tax | 1.09B | 408M | 1.56B | 2.81B | 1.51B | 2.55B | 2.57B | 2.37B | 2B | 1.64B | 3.32B | 3.39B | 3.03B | 2.93B | 2.44B | 2.26B | 2.18B | 2.2B | 2.19B | 1.72B | 856.9M | 684.3M | 477.6M | 528.2M | 439.2M | 296.4M | 497.4M | 441.3M | 306.5M | 149.2M | 271M |
| Effective Tax Rate % | 8.96% | 19.1% | 25.41% | 25.11% | 25.86% | 24.18% | 26.29% | 26.3% | 142.39% | 19.8% | 38.4% | 39.3% | 39.5% | 38.89% | 38.64% | 39.29% | 38.9% | 37.29% | 39.61% | 39.5% | 38.5% | 35.85% | 34.2% | 38.4% | 38% | 41.77% | 40% | 41% | 44.36% | 62.79% | 42.12% |
| Net Income | 11.05B | 1.77B | 4.61B | 8.34B | 4.31B | 8B | 7.18B | 6.63B | -594M | 6.62B | 5.32B | 5.24B | 4.64B | 4.59B | 3.86B | 3.46B | 3.43B | 3.7B | 3.21B | 2.64B | 1.37B | 1.22B | 918.8M | 847.3M | 716.6M | 413.2M | 746M | 635.1M | 384.5M | 88.8M | 208.2M |
| Net Margin % | 2.63% | 0.44% | 1.24% | 2.33% | 1.34% | 2.74% | 2.67% | 2.58% | -0.31% | 3.58% | 2.99% | 3.42% | 3.33% | 3.62% | 3.14% | 3.23% | 3.58% | 3.76% | 3.67% | 3.45% | 3.12% | 3.31% | 3% | 3.19% | 2.96% | 1.86% | 3.71% | 3.51% | 2.52% | 0.65% | 1.76% |
| Net Income Growth % | 2256.72% | -61.68% | -44.7% | 93.55% | -46.12% | 11.45% | 8.22% | 1216.84% | -108.97% | 24.54% | 1.53% | 12.77% | 1.13% | 18.84% | 11.61% | 1.02% | -7.28% | 15.07% | 21.81% | 92.64% | 11.77% | 33.29% | 8.44% | 18.24% | 73.43% | -44.61% | 17.46% | 65.18% | 333% | -57.35% | 136.35% |
| EPS (Diluted) | 8.56 | 1.39 | 3.66 | 6.47 | 3.26 | 5.95 | 5.46 | 5.08 | -0.57 | 6.44 | 4.90 | 4.63 | 3.96 | 3.74 | 3.03 | 2.57 | 2.49 | 2.55 | 2.18 | 1.92 | 1.60 | 1.45 | 1.10 | 1.03 | 0.88 | 0.50 | 0.92 | 0.78 | 0.48 | 0.10 | 0.26 |
| EPS Growth % | 2160.53% | -62.02% | -43.43% | 98.47% | -45.21% | 8.97% | 7.48% | 991.23% | -108.85% | 31.43% | 5.83% | 16.92% | 5.88% | 23.43% | 17.9% | 3.21% | -2.35% | 16.97% | 13.54% | 20% | 10.34% | 31.82% | 6.8% | 17.05% | 76% | -45.65% | 17.95% | 62.5% | 405.26% | -63.46% | 117.11% |
| EPS (Basic) | - | 1.40 | 3.66 | 6.49 | 3.29 | 6.00 | 5.48 | 5.10 | -0.57 | 6.47 | 4.93 | 4.66 | 3.98 | 3.77 | 3.05 | 2.59 | 2.51 | 2.58 | 2.23 | 1.97 | 1.65 | 1.49 | 1.13 | 1.06 | 0.90 | 0.51 | 0.94 | 0.80 | 0.48 | 0.10 | 0.27 |
| Diluted Shares Outstanding | 1.29B | 1.27B | 1.26B | 1.29B | 1.32B | 1.33B | 1.31B | 1.3B | 1.04B | 1.02B | 1.08B | 1.13B | 1.17B | 1.23B | 1.28B | 1.35B | 1.38B | 1.45B | 1.47B | 1.37B | 853.2M | 841.6M | 822.36M | 808.45M | 810.6M | 797M | 799.34M | 817.8M | 810.4M | 790.53M | 426.4M |
Quick answers to the most common questions about buying CVS stock.
For fiscal year 2025, CVS Health Corp. (CVS) reported total revenue of $402.07B. This represents a 3298.2% increase compared to $11.83B in 1996.
CVS Health Corp. (CVS) is profitable, generating $1.77B in net income for the fiscal year ending 2025 with a net profit margin of 0.4%.
CVS Health Corp. (CVS) reported an operating income of $10.38B, resulting in an operating profit margin of 2.6%. This margin reflects the operational efficiency of the business before interest and taxes.
CVS Health Corp. (CVS) generated $55.36B in gross profit for the year, representing a gross profit margin of 13.8%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Regulatory scrutiny of vertical integration
Metrics are mathematically derived from official filings.
Revenue Growth Holds Near Mid-Single Digits
Based on EDBL's reported figures, CVS revenue reached $108.4B in 2026Q3 with year-over-year growth of 5.4%, decelerating from 8.4% in 2025Q2, suggesting top-line momentum is moderating from its earlier pace.
The revenue trajectory reflects a mature, scale-driven pharmacy and insurance base where growth is increasingly dependent on membership gains and PBM volume rather than pricing power. The deceleration from high-single-digit rates through 2025 suggests the expansion is maturing, and investors should monitor whether Medicare Advantage membership growth can offset softer retail traffic. Sustained growth below 6% would indicate the integrated model is increasingly reliant on acquisitions to sustain top-line expansion.
Combined Ratio Tightens But Stays Near 100%
As reported in financial statements, CVS combined ratio improved to 96.7% in 2026Q3 from 103.1% in 2025Q3, indicating underwriting results have moved closer to breakeven after a quarter of significant strain.
A combined ratio consistently in the mid-90s leaves a thin underwriting margin, meaning the insurance arm contributes limited cushion against medical cost volatility. The loss ratio of 86.3% in 2026Q3 is elevated relative to earlier periods, which may reflect senior utilization pressure noted in the reported risk profile. Investors should watch whether the recent improvement reflects durable cost containment or a temporary utilization lull.
Earnings Volatility Tied to Reserve Quality
According to recent SEC filings, CVS net income swung from a $4.0B loss in 2025Q3 to $2.2B profit in 2026Q3, a pattern that may partly reflect reserve adjustments and warrants further investigation.
The sharp quarterly swings in net income relative to comparatively stable revenue suggest that reserve development and one-time items are driving a meaningful share of reported earnings. Because the reported figures do not isolate prior-year development, the degree to which earnings are inflated or depressed by reserve changes cannot be confirmed from the data provided. Analysts should seek the prior-year development disclosure to assess whether current profitability is structurally sustainable.
Thin Operating Margin Limits Capital Flexibility
Based on reported figures, CVS operating income of $3.6B on $108.4B revenue in 2026Q3 implies an operating margin near 3.3%, leaving limited cushion given debt-to-equity of 1.24.
A margin of this magnitude provides little buffer against rising medical costs or integration expenses from recent acquisitions. Combined with elevated leverage, the company has less room to absorb an adverse utilization shock without pressure on debt service or dividend capacity. Investors should monitor whether operating income growth can keep pace with interest obligations.
Earnings Beat May Reflect Non-Recurring Items
As reported in financial statements, the 2026Q3 EPS of $2.2B net income against a 0.4% net margin suggests the earnings beat could be driven by items that do not repeat, warranting caution.
The gap between a strong EPS beat and a net margin near 0.4% suggests that headline earnings may be sensitive to a small number of large items rather than broad operating improvement. If the beat reflects reserve releases or timing effects, the apparent momentum may not persist into subsequent quarters. Investors should treat the raised guidance as provisional until margin improvement is confirmed across multiple periods.